Crystal structure of a human membrane protein involved in cysteinyl leukotriene biosynthesis

Article metrics


The cysteinyl leukotrienes, namely leukotriene (LT)C4 and its metabolites LTD4 and LTE4, the components of slow-reacting substance of anaphylaxis1,2, are lipid mediators of smooth muscle constriction3,4,5 and inflammation6,7, particularly implicated in bronchial asthma8,9. LTC4 synthase (LTC4S), the pivotal enzyme for the biosynthesis of LTC4 (ref. 10), is an 18-kDa integral nuclear membrane protein11,12 that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (MGSTs), and microsomal prostaglandin E synthase 1 (ref. 13). LTC4S conjugates glutathione to LTA4, the endogenous substrate derived from arachidonic acid through the 5-lipoxygenase pathway14. In contrast with MGST2 and MGST3 (refs 15, 16), LTC4S does not conjugate glutathione to xenobiotics17. Here we show the atomic structure of human LTC4S in a complex with glutathione at 3.3 Å resolution by X-ray crystallography and provide insights into the high substrate specificity for glutathione and LTA4 that distinguishes LTC4S from other MGSTs. The LTC4S monomer has four transmembrane α-helices and forms a threefold symmetric trimer as a unit with functional domains across each interface. Glutathione resides in a U-shaped conformation within an interface between adjacent monomers, and this binding is stabilized by a loop structure at the top of the interface. LTA4 would fit into the interface so that Arg 104 of one monomer activates glutathione to provide the thiolate anion that attacks C6 of LTA4 to form a thioether bond, and Arg 31 in the neighbouring monomer donates a proton to form a hydroxyl group at C5, resulting in 5(S)-hydroxy-6(R)-S-glutathionyl-7,9-trans-11,14-cis-eicosatetraenoic acid (LTC4). These findings provide a structural basis for the development of LTC4S inhibitors for a proinflammatory pathway mediated by three cysteinyl leukotriene ligands whose stability and potency are different and by multiple cysteinyl leukotriene receptors whose functions may be non-redundant.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Structure of LTC 4 S.
Figure 2: GSH-binding site at the interface of monomers C and A.
Figure 3: The V-shaped valley as the putative LTA 4 -binding site.


  1. 1

    Kellaway, C. H. & Trethewie, W. R. The liberation of a slow reacting smooth muscle-stimulating substance in anaphylaxis. Q. J. Exp. Physiol. 30, 121–145 (1940)

  2. 2

    Brocklehurst, W. E. The release of histamine and formation of a slow-reacting substance (SRS-A) during anaphylactic shock. J. Physiol. (Lond.) 151, 416–435 (1960)

  3. 3

    Dahlen, S. E., Hedqvist, P., Hammarstrom, S. & Samuelsson, B. Leukotrienes are potent constrictors of human bronchi. Nature 288, 484–486 (1980)

  4. 4

    Dahlen, S. E. et al. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. Proc. Natl Acad. Sci. USA 78, 3887–3891 (1981)

  5. 5

    Soter, N. A., Lewis, R. A., Corey, E. J. & Austen, K. F. Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4) in human skin. J. Invest. Dermatol. 80, 115–119 (1983)

  6. 6

    Beller, T. C. et al. Cysteinyl leukotriene 1 receptor controls the severity of chronic pulmonary inflammation and fibrosis. Proc. Natl Acad. Sci. USA 101, 3047–3052 (2004)

  7. 7

    Kim, D. C. et al. Cysteinyl leukotrienes regulate Th2 cell-dependent pulmonary inflammation. J. Immunol. 176, 4440–4448 (2006)

  8. 8

    Weiss, J. W. et al. Bronchoconstrictor effects of leukotriene C in humans. Science 216, 196–198 (1982)

  9. 9

    Manning, P. J. et al. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist. N. Engl. J. Med. 323, 1736–1739 (1990)

  10. 10

    Kanaoka, Y., Maekawa, A., Penrose, J. F., Austen, K. F. & Lam, B. K. Attenuated zymosan-induced peritoneal vascular permeability and IgE-dependent passive cutaneous anaphylaxis in mice lacking leukotriene C4 synthase. J. Biol. Chem. 276, 22608–22613 (2001)

  11. 11

    Lam, B. K., Penrose, J. F., Freeman, G. J. & Austen, K. F. Expression cloning of a cDNA for human leukotriene C4 synthase, an integral membrane protein conjugating reduced glutathione to leukotriene A4 . Proc. Natl Acad. Sci. USA 91, 7663–7667 (1994)

  12. 12

    Welsch, D. J. et al. Molecular cloning and expression of human leukotriene-C4 synthase. Proc. Natl Acad. Sci. USA 91, 9745–9749 (1994)

  13. 13

    Bresell, A. et al. Bioinformatic and enzymatic characterization of the MAPEG superfamily. FEBS J. 272, 1688–1703 (2005)

  14. 14

    Samuelsson, B., Dahlen, S. E., Lindgren, J. A., Rouzer, C. A. & Serhan, C. N. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 237, 1171–1176 (1987)

  15. 15

    Jakobsson, P. J., Mancini, J. A. & Ford-Hutchinson, A. W. Identification and characterization of a novel human microsomal glutathione S-transferase with leukotriene C4 synthase activity and significant sequence identity to 5-lipoxygenase-activating protein and leukotriene C4 synthase. J. Biol. Chem. 271, 22203–22210 (1996)

  16. 16

    Jakobsson, P. J., Mancini, J. A., Riendeau, D. & Ford-Hutchinson, A. W. Identification and characterization of a novel microsomal enzyme with glutathione-dependent transferase and peroxidase activities. J. Biol. Chem. 272, 22934–22939 (1997)

  17. 17

    Yoshimoto, T., Soberman, R. J., Spur, B. & Austen, K. F. Properties of highly purified leukotriene C4 synthase of guinea pig lung. J. Clin. Invest. 81, 866–871 (1988)

  18. 18

    Schmidt-Krey, I. et al. Human leukotriene C4 synthase at 4.5 Å resolution in projection. Structure 12, 2009–2014 (2004)

  19. 19

    Holm, P. J. et al. Structural basis for detoxification and oxidative stress protection in membranes. J. Mol. Biol. 360, 934–945 (2006)

  20. 20

    Thoren, S. et al. Human microsomal prostaglandin E synthase-1: purification, functional characterization, and projection structure determination. J. Biol. Chem. 278, 22199–22209 (2003)

  21. 21

    Christmas, P., Weber, B. M., McKee, M., Brown, D. & Soberman, R. J. Membrane localization and topology of leukotriene C4 synthase. J. Biol. Chem. 277, 28902–28908 (2002)

  22. 22

    Armstrong, R. N. Structure, catalytic mechanism, and evolution of the glutathione transferases. Chem. Res. Toxicol. 10, 2–18 (1997)

  23. 23

    Lam, B. K., Penrose, J. F., Xu, K., Baldasaro, M. H. & Austen, K. F. Site-directed mutagenesis of human leukotriene C4 synthase. J. Biol. Chem. 272, 13923–13928 (1997)

  24. 24

    Guillen Schlippe, Y. V. & Hedstrom, L. A twisted base? The role of arginine in enzyme-catalyzed proton abstractions. Arch. Biochem. Biophys. 433, 266–278 (2005)

  25. 25

    Zimmer, J. S., Dyckes, D. F., Bernlohr, D. A. & Murphy, R. C. Fatty acid binding proteins stabilize leukotriene A4: competition with arachidonic acid but not other lipoxygenase products. J. Lipid Res. 45, 2138–2144 (2004)

  26. 26

    Marfat, A. & Corey, E. J. Synthesis and structure elucidation of leukotrienes. Adv. Prostaglandin Thromboxane Leukot. Res. 14, 155–228 (1985)

  27. 27

    Collaborative Computational Project Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50, 760–763 (1994)

  28. 28

    Jones, T. A., Zou, J. Y., Cowan, S. W. & Kjeldgaard, M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 47, 110–119 (1991)

  29. 29

    Brünger, A. T. et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54, 905–921 (1998)

  30. 30

    Adachi, S. et al. The RIKEN structural biology beamline II (BL44B2) at the SPring-8. Nucl. Instrum. Methods Phys. Res. A 467–468, 711–714 (2001)

  31. 31

    Sheldrick, G. M. Macromolecular phasing with SHELXE. Z. Kristallogr. 217, 644–650 (2002)

Download references


We thank T. Tsurumura and N. Takahashi for their technical assistance. This work was supported by Tanpaku3000 of MEXT (to M.M.), RIKEN Matching fund (to H.A. and M.M.) and National Institutes of Health grants (to Y.K., B.K.L. and K.F.A.).

Author Contributions H.A., Y.K. and D.I. contributed equally to this work. Y.K. overexpressed and purified the human LTC4S. H.A. optimized the enzyme purification methods. H.A., D.I. and T.S. crystallized the enzyme. D.I. prepared the SeMet protein. H.A. and M.M. solved the structure. B.K.L. performed the LTC4S assay. H.A., Y.K., K.F.A. and M.M. guided the work and prepared the manuscript. All authors discussed the results and commented on the manuscript.

Coordinates and structure factors have been deposited in the Protein Data Bank with the accession number 2PNO.

Author information

Correspondence to K. Frank Austen or Masashi Miyano.

Ethics declarations

Competing interests

Reprints and permissions information is available at The authors declare no competing financial interests.

Supplementary information

Supplementary Information

This file contains Supplementary Figures S1-S3 with Legends and Table S1 with crystallographic statistics. (PDF 3422 kb)

Rights and permissions

Reprints and Permissions

About this article

Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.